Date of Award
2027
Document Type
Capstone
Degree Name
Master of Science (MS)
Department
Physician Assistant Studies
Committee Chair
LaDonna Clark
Abstract
Introduction: Type two diabetes contributes to chronic kidney disease progression in a multitude of ways within metabolic and hemodynamic factors. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, offers new solutions in slowing or stopping kidney disease progression in type two diabetics. The purpose of this review is to understand if adding finerenone can help slow kidney disease progression in adults with type two diabetes already receiving RAS inhibition.
Methods: A specific PubMed search with keywords including “type two diabetes”, “kidney disease” and “finerenone”, with filters and operators applied, supplied four articles for review.
Results: Finerenone was associated with decreased primary kidney outcomes in type two diabetics compared to placebo and was associated with helpful effects on eGFR and urine albumin-to-creatinine ratio. Finerenone treatment groups were associated with more hyperkalemia-associated adverse events compared to placebo.
Discussion: Finerenone appears to have a helpful effect in slowing or stopping kidney disease progression in type two diabetics, but more work needs to be done to evaluate how effective it is long term, as well as compared in head-to-head studies to current standard therapy. Hyperkalemia is an important side effect that needs continuous monitoring during treatment.
Recommended Citation
Elgas EC. Evaluating Finerenone for Kidney Disease Progression in Patients with Type Two Diabetes and Chronic Kidney Disease. The PA Department Journal of Medical Science. 2026. https://digitalcommons.gardner-webb.edu/pa-department-journal-of-medical-science/86
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License